Global Computational Biology Market Size to Hit USD 39.38 Billion by 2032: AI, Bioinformatics & Drug Discovery Lead the Way

According to the latest report from Straits Research, The global computational biology market is expected to reach USD 39.38 billion in 2032, growing at a CAGR of 19.9% during the forecast period (2024-2032), driven by advancements in AI and machine learning technologies transforming drug discovery and personalized medicine.

Computational biology a discipline that uses computer science and advanced analytics to model, simulate and interpret biological systems has been increasingly critical to drug discovery, disease modelling, genomics, and personalised medicine. The growth is being driven by an explosion of biological data, rising bioinformatics research, growing clinical studies in pharmacogenomics and pharmacokinetics, and the adoption of AI/ML for predictive modelling.

View the full report for complete insights and forecasts: https://straitsresearch.com/report/computational-biology-market

Market Introduction:
As genome sequencing initiatives proliferate and biological data sets expand exponentially, the demand for computational tools, databases, hardware and analytics services has surged. Academic institutions, biotech/pharma companies and research labs are leveraging computational biology to accelerate target identification, optimise lead discovery, model disease progression and personalise therapies. These forces are co‐alescing into high growth for the computational biology market.

Major Growth Drivers:
Increase in Bioinformatics Research - With organisations establishing dedicated centres (for example, the Centre for Bioinformatics & Computational Biology at NIT‐R India) to analyse vast data sets and unlock disease biomarkers, the foundation for computational biology's growth is expanding.

Rising Number of Clinical Studies in Pharmacogenomics & Pharmacokinetics - As drug developers increasingly adopt pharmacogenomic testing and PK/PD modelling, the need for computational biology solutions grows.

AI & Machine Learning Integration - AI‐enabled platforms are enabling more accurate and faster modelling of biological systems, enhancing drug discovery and disease simulation, which is elevating demand for computational biology tools across the value chain.

Restraints:
Despite strong growth, the market faces some challenges:

Lack of Trained Professionals - Many organisations report a shortage of skilled computational biologists, analysts and data scientists, constraining deployment and scaling of solutions.

High Cost of Infrastructure & Data Management - High‐performance computing, large‐scale databases and advanced software packages require significant investment, which may present barriers especially in smaller research centres or emerging economies.

Opportunities:
Innovative Technologies - Advances such as cloud‐based platforms, automation in biology labs, robotics and deeper integration of AI/ML are opening new avenues for growth.

Outsourcing & Contract Services - The contract services segment is growing rapidly, providing cost‐effective access to expertise and infrastructure.

Regional Insights;
North America remains the dominant region, powered by strong bioinformatics research, robust drug development pipelines, and substantial investment in computational biology.

Europe is a strong second, with Germany and other countries emphasising drug discovery R&D and computational modelling capabilities.

Asia‐Pacific is the fastest growing region, supported by expanding life‐sciences infrastructure, rising healthcare investment, and increasing computational biology adoption in countries like China and India.

Download a free sample to explore key drivers and segment data: https://straitsresearch.com/report/computational-biology-market/request-sample

Competitive Landscape:
The market is broad and features a range of established companies and innovative players. Key players include:

Thermo Fisher Scientific Inc.
Illumina, Inc.
Qiagen N.V.
Dassault Systèmes SE
Certara
Chemical Computing Group ULC
Compugen Ltd
Rosa & Co. LLC
Genedata AG

These companies are investing in advanced compute platforms, AI/ML solutions, multi‐omics integration and partnerships with pharma/biotech to strengthen their positioning in the computational biology space.

Get the full report to access detailed datasets and strategies: https://straitsresearch.com/buy-now/computational-biology-market

Conclusion:
In summary, the global computational biology market stands at a critical inflection point. The convergence of biology and computation, rapid data growth, and demand for personalised therapeutics are driving the expansion. Organisations that harness scalable analytics, deploy robust infrastructure and build internal expertise will be best positioned to capitalise on the USD 39 billion opportunity by 2032. As the field evolves, we expect computational biology to become deeply embedded in drug pipelines, research labs, clinical development and beyond.

Contact Us :
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

About Us :
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

This release was published on openPR.